This Letter to the Editor originally appeared in Bloomberg on October 5, 2023 The Bloomberg editorial board’s article calling the rationale for opposition from the disability community to the use of quality-adjusted life years, or QALYs, “dubious” dismisses decades of evidence that these types of measures discriminate. |
In this week's edition...
— PIPC Chair Tony Coelho Testifies to Massachusetts Legislature Supporting Statewide QALY Ban, Michigan Bill Threatens Expanded Use of QALYs and Similar Measures. See details below. — ICER Finalizes 2023 Updates to Value Assessment Framework. See details below. — Comments on Proposed Rule on Accessibility of Web Information and Services of State and Local Government Entities Due October 3. See details below. — PCORI Seeks Nominations for Advisory Panels. Click here to learn more, to apply to serve on an advisory panel, or submit a nomination. — CMS Process Should Provide Robust and Ongoing Engagement of Patients and People with Disabilities in Negotiation Process. See details below. — Letter from Over 1900 Researchers, Organizations and Individuals Opposing NIMHD Exclusion of People with Disabilities. See details below. — Emerging Threats in States for Use of Discriminatory Metrics. See details below. — What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below. — ICER's QALY-Based Study Topics. See details below. — Upcoming Events and Webinars. See details below. — AHRQ Effective Program Updates. See details below. — Job Openings. See details below. PIPC Chair Tony Coelho Testifies to Massachusetts Legislature Supporting Statewide QALY Ban9/20/2023
In this week's edition...
— PCORI Seeks Nominations for Advisory Panels. Click here to learn more, to apply to serve on an advisory panel, or submit a nomination. — CMS Process Should Provide Robust and Ongoing Engagement of Patients and People with Disabilities in Negotiation Process. See details below. — Letter from Over 1400 Researchers, Organizations and Individuals Opposing NIMHD Exclusion of People with Disabilities. See details below. — Statement from PIPC Chairman Tony Coelho on the Proposed Section 504 Rule. See details below. — PIPC Statement on Selection of Drugs Under Medicare Drug Price Negotiation Program Guidance. Click here to read the statement. — National Forum for Heart Disease and Stroke Prevention Annual Meeting October 26. Click here to register to attend in person or virtually. — Emerging Threats in States for Use of Discriminatory Metrics. See details below. — What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below. — ICER's QALY-Based Study Topics. See details below. — Upcoming Events and Webinars. See details below. — AHRQ Effective Program Updates. See details below. — Job Openings. See details below. In this week's edition...
— Statement from PIPC Chairman Tony Coelho on the Proposed Section 504 Rule. See details below. — Letter from Over 1400 Researchers, Organizations and Individuals Opposing NIMHD Exclusion of People with Disabilities. See details below. — PIPC Statement on Selection of Drugs Under Medicare Drug Price Negotiation Program Guidance. Click here to read the statement. — PIPC Offers Comments on Transitional Coverage for Emerging Technologies. Click here to read the letter. — National Forum for Heart Disease and Stroke Prevention Annual Meeting October 26. Click here to register to attend in person or virtually. — Emerging Threats in States for Use of Discriminatory Metrics. See details below. — What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below. — ICER's QALY-Based Study Topics. See details below. — Upcoming Events and Webinars. See details below. — AHRQ Effective Program Updates. See details below. — Job Openings. See details below. PIPC Statement on Selection of Drugs under Medicare Drug Price Negotiation Program Guidance8/29/2023
In this week's edition...
— PIPC Submits Comments on ICER Assessment of MLD Treatments. Click here to read the letter. — PIPC Submits Comments on CMS Proposed Guidance for Coverage with Evidence Development. Click here to read the article. — Takeaways from AcademyHealth’s Organizational Briefing with PCORI Executive Director Nakela Cook. Click here to read the blog. — ICHOM Seeks Input on Patient Charter. See details below. — Emerging Threats in States for Use of Discriminatory Metrics. See details below. — What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below. — ICER's QALY-Based Study Topics. See details below. — Upcoming Events and Webinars. See details below. — AHRQ Effective Program Updates. See details below. — Job Openings. See details below. In this week's edition...
— PIPC Submits Comments on CMS Proposed Guidance for Coverage with Evidence Development. Click here to read the article. — ICHOM Seeks Input on Patient Charter. See details below. — New ASPE Report Assesses Relevant Outcomes for Patient-Centered Outcomes Research. See details below. — Patient Engagement Is Key to the Success of Value-Based Care Programs. Click here to read the column. — AAPD: What Health Equity Means to the Disability Community. Click here to read the blog. — Drugs Extending My Life, but Boston Institute Disagrees. Click here to read the op-ed. — Emerging Threats in States for Use of Discriminatory Metrics. See details below. — What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below. — ICER's QALY-Based Study Topics. See details below. — Upcoming Events and Webinars. See details below. — AHRQ Effective Program Updates. See details below. — Job Openings. See details below. In this week's edition...
— Drugs Extending My Life, but Boston Institute Disagrees. Click here to read the op-ed. — How CMS Can Advance – or Impede – Patient-Centered Decision-Making in its New Drug Pricing Program. Click here to read the column, — QALYs: The Math Doesn’t Work. Click here to read the article. — Opinion: Drug Pricing and the 'Impossible Trinity' for Patients. Click here to read the op-ed. — PIPC Collaborates with Avalere on Investigation of Use of Patient-Centered Outcomes in Value Assessment. See details below. — CCD Pens Letter of Support for Protecting Healthcare for All Patients Act. Click here to read the letter. — Chairman's Corner: I introduced the ADA 35 years ago. Now Congress needs to act to ban a practice that devalues disabled lives. Click here to read the op-ed. — Emerging Threats in States for Use of Discriminatory Metrics. See details below. — What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below. — ICER's QALY-Based Study Topics. See details below. — Upcoming Events and Webinars. See details below. — AHRQ Effective Program Updates. See details below. The Partnership to Improve Patient Care (PIPC) has long expressed frustration with value assessments of health care that fail to incorporate outcomes that matter to patients into their conclusions about what care may be worth. We commissioned Avalere to do a deep dive to better understand how the Institute for Clinical and Economic Review (ICER) integrates patient input and preferences in its value assessments. In this week's edition...
— Chairman's Corner: I introduced the ADA 35 years ago. Now Congress needs to act to ban a practice that devalues disabled lives. Click here to read the op-ed. — PIPC Statement on Drug Negotiation Guidance. See details below. — Over 75 Leading Patient Groups Join PIPC Comment Letter on ICER 2024 Value Assessment Framework. Click here to read the letter. — PCORI Opens Applications for October 2023 Funding Announcements. See details below. — Follow PIPC on LinkedIn! Click here to view the page. — Emerging Threats in States for Use of Discriminatory Metrics. See details below. — What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below. — ICER's QALY-Based Study Topics. See details below. — Upcoming Events and Webinars. See details below. — AHRQ Effective Program Updates. See details below. — Job Openings. See details below.
In this week's edition...
— Over 75 Leading Patient Groups Join PIPC Comment Letter on ICER 2024 Value Assessment Framework. Click here to read the letter. — PIPC Statement on Drug Negotiation Guidance. See details below. — PIPC Submits Comments on FDA Guidance on Patient-Focused Drug Development. Click here to read the letter. — With Guidance from the Field, AHRQ Launches an Ambitious Strategy for Patient-Centered Outcomes Research. Click here to read the blog. — Follow PIPC on LinkedIn! Click here to view the page. — Emerging Threats in States for Use of Discriminatory Metrics. See details below. — What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below. — ICER's QALY-Based Study Topics. See details below. — Upcoming Events and Webinars. See details below. — AHRQ Effective Program Updates. See details below. — Job Openings. See details below. |
Topics
All
Archives
March 2024
|